From 012c68a57ebdbcee0005a9c50badd2bd791e65ec Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Sun, 3 May 2026 04:36:35 +0000 Subject: [PATCH] vida: extract claims from 2026-05-03-lancet-psychiatry-swedish-glp1-mental-health-worsening-cohort - Source: inbox/queue/2026-05-03-lancet-psychiatry-swedish-glp1-mental-health-worsening-cohort.md - Domain: health - Claims: 1, Entities: 0 - Enrichments: 2 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida --- ...-through-mesolimbic-dopamine-modulation.md | 7 +++++++ ...uction-through-vta-dopamine-suppression.md | 9 ++++++++- ...nts-through-glp1r-psychiatric-mechanism.md | 19 +++++++++++++++++++ ...ish-glp1-mental-health-worsening-cohort.md | 5 ++++- 4 files changed, 38 insertions(+), 2 deletions(-) create mode 100644 domains/health/semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism.md rename inbox/{queue => archive/health}/2026-05-03-lancet-psychiatry-swedish-glp1-mental-health-worsening-cohort.md (98%) diff --git a/domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md b/domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md index c5838cf0d..0d7514862 100644 --- a/domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md +++ b/domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md @@ -81,3 +81,10 @@ Concurrent psychotropic medication use (antidepressants, benzodiazepines) shows **Source:** The Lancet 2026, EVOKE/EVOKE+ Phase 3 failure EVOKE/EVOKE+ Alzheimer's failure provides critical boundary evidence for GLP-1 CNS mechanism specificity. Semaglutide succeeds in addiction (VTA dopamine reward circuits) but fails in neurodegeneration (amyloid/tau pathways), demonstrating that GLP-1 receptor activation produces pathway-specific effects rather than broad neuroprotection. This supports the mesolimbic dopamine mechanism for addiction while ruling out generalized CNS benefit claims. + + +## Extending Evidence + +**Source:** Lancet Psychiatry 2026, Karolinska active-comparator cohort + +Swedish national cohort (n=95,490) shows semaglutide reduces depression worsening 44% and anxiety worsening 38% in patients with pre-existing diagnoses, with drug-specific effects (liraglutide 18%, exenatide/dulaglutide no effect). This extends the mesolimbic dopamine modulation mechanism from AUD to mood disorders, suggesting broader psychiatric protective effects beyond substance use. diff --git a/domains/health/semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression.md b/domains/health/semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression.md index e1525e931..c55f745ff 100644 --- a/domains/health/semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression.md +++ b/domains/health/semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression.md @@ -11,7 +11,7 @@ sourced_from: health/2026-04-24-hendershot-jama-psychiatry-semaglutide-aud-rct.m scope: causal sourcer: Hendershot CS et al. supports: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"] -related: ["hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression"] +related: ["hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population"] --- # Semaglutide produces large-effect-size reductions in alcohol consumption and craving through VTA dopamine reward circuit suppression @@ -31,3 +31,10 @@ Meta-analysis confirms semaglutide as best-performing agent for alcohol reductio **Source:** Qeadan F et al., Addiction 2025 Real-world observational data from 817,309 AUD patients (5,621 with GLP-1 RA) shows 50% lower alcohol intoxication rates (IRR 0.50, 95% CI 0.40-0.63) over 24 months, consistent with Hendershot RCT findings. Effect maintained across T2DM (IRR 0.51), obesity (IRR 0.58), and combined conditions (IRR 0.58) subgroups. Provides population-scale corroboration of the VTA dopamine mechanism hypothesis, though observational confounding limits causal inference. + + +## Extending Evidence + +**Source:** Lancet Psychiatry 2026, n=95,490 Swedish cohort + +The 44% depression worsening reduction in Swedish cohort provides additional evidence for VTA dopamine pathway modulation, as depression and addiction share overlapping reward circuitry. The drug-specific effect (semaglutide >> liraglutide >> exenatide/dulaglutide) mirrors AUD findings and suggests potency-dependent CNS penetration. diff --git a/domains/health/semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism.md b/domains/health/semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism.md new file mode 100644 index 000000000..10b21fda1 --- /dev/null +++ b/domains/health/semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism.md @@ -0,0 +1,19 @@ +--- +type: claim +domain: health +description: Active-comparator cohort study of 95,490 Swedish patients shows semaglutide outperforms other GLP-1 RAs on mental health outcomes, suggesting drug-specific mechanism beyond metabolic effects +confidence: likely +source: Lancet Psychiatry 2026, Karolinska Institutet national cohort study +created: 2026-05-03 +title: Semaglutide reduces depression worsening by 44 percent in patients with pre-existing depression through GLP-1R-mediated psychiatric protective effects +agent: vida +sourced_from: health/2026-05-03-lancet-psychiatry-swedish-glp1-mental-health-worsening-cohort.md +scope: causal +sourcer: Lancet Psychiatry / Karolinska Institutet +supports: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation"] +related: ["the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth", "social-isolation-costs-medicare-7-billion-annually-and-carries-mortality-risk-equivalent-to-smoking-15-cigarettes-per-day-making-loneliness-a-clinical-condition-not-a-personal-problem", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss-suggesting-glp1r-specific-cardiac-mechanism", "real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss"] +--- + +# Semaglutide reduces depression worsening by 44 percent in patients with pre-existing depression through GLP-1R-mediated psychiatric protective effects + +A Swedish national cohort study of 95,490 adults with diagnosed depression, anxiety, or both found semaglutide associated with 44% lower risk of worsening depression (aHR 0.56) and 38% lower risk of worsening anxiety compared to other antidiabetic medications. The study used an active-comparator design comparing GLP-1 RAs to other antidiabetic drugs, minimizing healthy-user bias that plagued earlier observational studies. Critically, the effect was drug-specific: liraglutide showed only 18% risk reduction, while exenatide and dulaglutide showed no significant effect. This within-class variation suggests the mechanism is not simply GLP-1 class effect but relates to semaglutide-specific properties—possibly higher GLP-1R agonism potency or superior CNS penetration. The study explicitly addresses the indication bias problem that affected the Session 34 '195% MDD risk' finding: by comparing GLP-1 users to other diabetic medication users (not untreated controls), it controls for the confounding where people with worse metabolic health have higher baseline depression rates. The magnitude of effect (44% reduction) is clinically substantial, not marginal. Multiple expert reactions confirmed methodological credibility despite observational design. This represents the strongest counter-evidence to GLP-1 psychiatric safety concerns and suggests GLP-1R agonism produces psychiatric protective effects independent of metabolic improvement. diff --git a/inbox/queue/2026-05-03-lancet-psychiatry-swedish-glp1-mental-health-worsening-cohort.md b/inbox/archive/health/2026-05-03-lancet-psychiatry-swedish-glp1-mental-health-worsening-cohort.md similarity index 98% rename from inbox/queue/2026-05-03-lancet-psychiatry-swedish-glp1-mental-health-worsening-cohort.md rename to inbox/archive/health/2026-05-03-lancet-psychiatry-swedish-glp1-mental-health-worsening-cohort.md index 84a74d2fe..13f3b4b63 100644 --- a/inbox/queue/2026-05-03-lancet-psychiatry-swedish-glp1-mental-health-worsening-cohort.md +++ b/inbox/archive/health/2026-05-03-lancet-psychiatry-swedish-glp1-mental-health-worsening-cohort.md @@ -7,10 +7,13 @@ date: 2026-03-22 domain: health secondary_domains: [] format: research-article -status: unprocessed +status: processed +processed_by: vida +processed_date: 2026-05-03 priority: high tags: [GLP-1, semaglutide, depression, anxiety, mental-health, psychiatric-safety, Swedish-cohort, pharmacoepidemiology] intake_tier: research-task +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content